Cortical glucose metabolism in Parkinson's disease without dementia

There have been several reports of decreased regional cerebral metabolic rates for glucose (rCMRglc) in Parkinson's disease (PD), although others find no differences between PD patients and controls. Differences in the cognitive status of the PD patients may account for some of these inconsistencies. We report the results of a PET study using 18F-fluorodeoxyglucose (FDG) to measure rCMRglc in eight nondemented PD patients, six of whom were receiving dopaminergic medications, and eight age-matched control subjects. We scanned one tomographic level through the temporal lobes that included both temporal neocortex and mesial temporal cortex, and one tomographic level through the basal ganglia that included frontal and parietal cortex. Previously determined rate constants and an operational equation were used to determine rCMRglc. On average, rCMRglc values were 23% below control values for all regions studied, with the greatest differences in posterior brain regions (visual association cortex, primary visual cortex, and parietal cortex) and thalamus. These results indicate that PD patients may show neocortical hypometabolism, especially in posterior brain regions, in the absence of any demonstrable cognitive deficits.

[1]  T. Ozawa,et al.  Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.

[2]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[3]  W. Jagust,et al.  Single‐Photon Emission Computed Tomography Studies of Regional Cerebral Blood Flow in Multiple Infarct Dementia , 1992 .

[4]  D Comar,et al.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[5]  R Harrop,et al.  Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease , 1986, Neurology.

[6]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[7]  J. Morrison,et al.  Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. , 1992, Archives of neurology.

[8]  B Mazoyer,et al.  Time course of effects of unilateral lesions of the nucleus basalis of Meynert on glucose utilization by the cerebral cortex. Positron tomography in baboons. , 1989, Brain : a journal of neurology.

[9]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[10]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[11]  K. Ebmeier,et al.  Cerebral blood flow measured by SPECT as a diagnostic tool in the study of dementia , 1989, Psychiatry Research.

[12]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[13]  Guillermo M. Alexander,et al.  Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease , 1985, Brain Research.

[14]  W. Jagust,et al.  Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  W. W. Moses,et al.  A positron tomograph with 600 BGO crystals and 2.6 mm resolution , 1988 .

[16]  A. Brun,et al.  Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading , 1981, Histopathology.

[17]  H. Mayberg,et al.  Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease , 1990, Annals of neurology.

[18]  D. Knopman,et al.  Dementia without Alzheimer pathology , 1985, Neurology.

[19]  M. Dam,et al.  [99mTc]-HM-PAO SPECT in Parkinson's Disease , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  D E Kuhl,et al.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.

[21]  W. Jagust,et al.  Cognitive correlates of regional cerebral blood flow in Alzheimer's disease. , 1993, Archives of neurology.

[22]  K. Jellinger,et al.  New developments in the pathology of Parkinson's disease. , 1990, Advances in neurology.

[23]  I. Mena,et al.  Temporal-parietal hypoperfusion with single-photon emission computerized tomography in conditions other than alzheimer’s disease , 1990 .

[24]  R J Wise,et al.  The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. , 1985, Brain : a journal of neurology.

[25]  J. Mcculloch,et al.  Cerebral circulation: effect of stimulation and blockade of dopamine receptors. , 1977, The American journal of physiology.

[26]  J V Haxby,et al.  High-resolution PET studies in Alzheimer's disease. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[27]  K Wienhard,et al.  Positron emission tomography in degenerative disorders of the dopaminergic system , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[28]  B Horwitz,et al.  Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. , 1988, Journal of clinical and experimental neuropsychology.

[29]  G. M. Halliday,et al.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease , 1990, Brain Research.

[30]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[31]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[32]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[33]  T. Joh,et al.  Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease , 1990, Annals of neurology.

[34]  J W Langston,et al.  Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.

[35]  J. Coyle,et al.  Jo U Rnal of Cerebral Blood Flow and Metabolism Decreased Cortical Glucose Utilization after Ibotenate Lesion of the Rat Ventromedial Globus Pallidus , 2022 .

[36]  A. Hakim,et al.  Dementia in Parkinson disease , 1979, Neurology.

[37]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[38]  T Jones,et al.  Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease , 1985, Neurology.

[39]  U. Slager,et al.  Pathologic correlates of dementia in Parkinson's disease. , 1986, Archives of neurology.

[40]  W. Jagust,et al.  Cognitive function and regional cerebral blood flow in Parkinson's disease. , 1992, Brain : a journal of neurology.

[41]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[42]  O. Hornykiewicz,et al.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.

[43]  M Schulzer,et al.  Cerebral glucose metabolism in Parkinson's disease with and without dementia. , 1992, Archives of neurology.

[44]  J. Haxby,et al.  Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. , 1986, Archives of neurology.

[45]  U. Roessmann,et al.  Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations , 1980, Annals of neurology.

[46]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[47]  M. Bergstrom,et al.  Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. , 1987, Advances in neurology.

[48]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[49]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[50]  J. Trenkler,et al.  Single photon emission computed tomography (SPECT) and x-ray CT in patients with dementia , 1989, Psychiatry Research.

[51]  D. D. Di Monte,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.

[52]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[53]  M C Bourdel,et al.  (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[54]  Stephen M. Stahl,et al.  Cerebral metabolism of Parkinsonian primates 21 days after MPTP , 1988, Experimental Neurology.

[55]  Richard S. J. Frackowiak,et al.  Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.